Canbridge Pharmaceuticals (HKSE:01228) Gross Margin % : 62.67% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Canbridge Pharmaceuticals's Gross Profit for the six months ended in Dec. 2023 was HK$41.0 Mil. Canbridge Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was HK$65.4 Mil. Therefore, Canbridge Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 62.67%.

The historical rank and industry rank for Canbridge Pharmaceuticals's Gross Margin % or its related term are showing as below:

HKSE:01228' s Gross Margin % Range Over the Past 10 Years
Min: 57.16 Med: 61.91 Max: 65.69
Current: 62.37

During the past 5 years, the highest Gross Margin % of Canbridge Pharmaceuticals was 65.69%. The lowest was 57.16%. And the median was 61.91%.

HKSE:01228's Gross Margin % is ranked better than
52% of 750 companies
in the Biotechnology industry
Industry Median: 60.88 vs HKSE:01228: 62.37

Canbridge Pharmaceuticals had a gross margin of 62.67% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Canbridge Pharmaceuticals was 0.00% per year.

Canbridge Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Canbridge Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Gross Margin % Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

65.69

57.16

60.26

61.91

62.37

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial				62.93	63.83	60.41	61.97	62.67

Competitive Comparison of Canbridge Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Canbridge Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's Gross Margin % falls into.

Canbridge Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Canbridge Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	70.2	/	112.518
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(112.518 - 42.337)	/	112.518
	=	62.37 %

Canbridge Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	41	/	65.43
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(65.43 - 24.428)	/	65.43
	=	62.67 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Canbridge Pharmaceuticals (HKSE:01228) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Canbridge Pharmaceuticals had a gross margin of 62.67% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Canbridge Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals (HKSE:01228) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals (HKSE:01228) Headlines

No Headlines